BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE

VolverGo back

Resultados 79 results. LastUpdate Updated on 30/01/2023 [11:36:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 150 días / Applications published in the last 150 days



Page1/4 nextPage   results/page


DIAGNOSING INFLAMMATORY BOWEL DISEASES

Publication No.: WO2023002491A1 26/01/2023

Applicant:

YEDA RES AND DEVELOPMENT CO LTD [IL]
TEL HASHOMER MEDICAL RES INFRASTRUCTURE AND SERVICES LTD [IL]

Absstract of: WO2023002491A1

A method of diagnosing an inflammatory bowel disease (IBD) of a subject is disclosed. The method comprises analyzing the RNA expression level of particular human gene in a fecal RNA sample of the subject, wherein when the expression level is above a predetermined amount it is indicative of the inflammatory bowel disease.

traducir

ANTIBODY COMBINATION AGAINST REGENERATING ISLET-DERIVED PROTEIN 1α AND DETECTION KIT COMPRISING SAME

Publication No.: WO2023284579A1 19/01/2023

Applicant:

SENBOLL BIOTECHNOLOGY CO LTD [CN]

CN_113248609_A

Absstract of: WO2023284579A1

The present invention provides an antibody combination that can be used to detect regenerating islet-derived protein 1α (REG1A), each antibody in the antibody combination can specifically bind to REG1A with high affinity so as to form a double-antibody sandwich form, thereby enabling qualitative and quantitative detection of human REG1A. The antibody combination or an ELISA detection kit comprising the antibody combination can be used for auxiliary diagnosis or disease risk prediction of REG1A-related diseases.

traducir

Method of Diagnosing and Treatment Monitoring of Crohn's Disease and Ulcerative Colitis

Publication No.: US2023015257A1 19/01/2023

Applicant:

UNIV MCMASTER [CA]

WO_2021113989_A1

Absstract of: US2023015257A1

Methods of diagnosing Crohn’s disease and ulcerative colitis in subjects is provided based on the determination of metabolites in urine samples, such as serine, hypoxanthine, kynurenine, threonine, dimethylglycine, tryptophan, indoxylsul-fate, phenylacetylglutamine, sialic acid, 5-hydroxy-6-indolyl-o-sulfate, 5-(Δ-carboxybutyl) homocysteine, and/or an anion having m/ z:RMT:polarity of 345.1553:0.770:n, or determination of metabolites in stool samples, such as ketodeoxycholic acid, cholic acid, choline, tryptophan, trimethyllysine, serine, butyric acid, lactic acid, hypoxanthine and/or guanine.

traducir

METHODS OF STRATIFYING AND TREATING A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS

Publication No.: US2023020356A1 19/01/2023

Applicant:

CEDARS SINAI MEDICAL CENTER [US]

CA_3121167_A1

Absstract of: US2023020356A1

Described herein are methods and systems for identifying subpopulations of patients having Crohn's disease, including populations at risk of developing structuring or other severe disease, and populations susceptible to success or failure with surgical intervention. Further provided are therapies useful for treating subpopulations of patients having Crohn's disease.

traducir

PREDICTION OF CLINICAL RESPONSE TO IL23-ANTAGONISTS USING IL23 PATHWAY BIOMARKERS

Publication No.: JP2023002583A 10/01/2023

Applicant:

アムジェンインコーポレイテッド

JP_2021170017_A

Absstract of: WO2017049035A1

The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an ant-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified., (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23 -mediated disease with a specific therapeutic agent.

traducir

DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE BASED ON GENES

Publication No.: KR20230003433A 05/01/2023

Applicant:

세다르스신나이메디칼센터

JP_2022095688_A

Absstract of: WO2017201461A1

The present invention describes a method of prognosing high or low probability of developing an inflammatory bowel disease (IBD) in a subject and a method of diagnosing an inflammatory bowel disease (IBD) in a subject. The invention further provides for a method of identifying genes/genetic loci associated with a disease condition, such as IBD, CD and/or UC.

traducir

SYSTEMS AND METHODS FOR IDENTIFYING MICROBIAL SIGNATURES

Publication No.: WO2023278352A1 05/01/2023

Applicant:

SUN GENOMICS INC [US]

Absstract of: WO2023278352A1

The present disclosure provides systems and methods for identifying microbial signatures from samples that determine discriminant features between healthy control populations and diseased subjects or populations with specific disorders. The microbial signatures are used to diagnose, prognose or determine risk and/or severity of a disease or disorder in a subject, such as autism spectrum disorder or irritable bowel syndrome.

traducir

DOSAGE REGIMEN FOR MADCAM ANTAGONISTS

Publication No.: EP4112079A1 04/01/2023

Applicant:

PFIZER [US]

ES_2927958_T3

Absstract of: WO2016110806A2

The present invention provides a method for the treatment of a patient comprising administering to the patient an initial dose of between about 1 mg and about 150 mg of a MAdCAM antagonist antibody. Biomarkers for assessing a patient's response to anti-MAdCAM treatment are also provided.

traducir

POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS

Publication No.: US2022411442A1 29/12/2022

Applicant:

WANG XIAODONG [US]
ZHONG HUA [US]

Absstract of: US2022411442A1

The present invention provides a genus of polycyclic amines that are useful as opioid receptor modulators. The compounds of the invention are useful in both therapeutic and diagnostic methods, including for treating pain, neurological disorders, cardiac disorders, bowel disorders, drug and alcohol addiction, drug overdose, urinary disorders, respiratory disorders, sexual dysfunction, psoriasis, graft rejection or cancer.

traducir

DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES

Publication No.: JP2022191343A 27/12/2022

Applicant:

武田薬品工業株式会社

BR_112016008975_PA

Absstract of: CA2927695A1

Methods, kits and compositions for diagnosing and treating autoimmue diseases such rheumatiodi arthritis, Crohn's disease, and ulcerative colitis.

traducir

Biomarker For Diagnosing Johne's Disease Comprising Alpha-2-Macroglobulin And Uses Thereof

Publication No.: US2022404372A1 22/12/2022

Applicant:

SEOUL NAT UNIV R&DB FOUNDATION [KR]
NAT UNIV GYEONGSANG IACF [KR]

KR_20220166962_PA

Absstract of: US2022404372A1

The present invention relates to a biomarker composition for diagnosing Johne's disease using the measurement of alpha-2-macrogolublin (A2M) and use thereof.Since the biomarker of the present invention can provide improved sensitivity to subclinical infections by revealing differences in the expressions of host proteins in the serum of MAP-infected subjects during various stages of JD progression, it can be effectively used to eradicate JD from a population of subjects. In particular, since the biomarker of the present invention is detected using the ELISA method, it is possible to diagnose Johne's disease more efficiently than when other methods such as mass spectrometry are used, and it can be directly applied in the field. In addition, it is possible to provide a more excellent diagnostic effect than the existing ELISA kits for diagnosing Johne's disease that are commercially available.

traducir

ANTI-TL1A (TNFSF15) ANTIBODY FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE

Publication No.: EP4105236A1 21/12/2022

Applicant:

CEDARS SINAI MEDICAL CENTER [US]

US_2022363745_A1

Absstract of: EP4105236A1

The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TH17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.

traducir

Biomarker For Diagnosing Johne's Disease Comprising Alpha-2-Macroglobulin And Uses Thereof

Publication No.: KR20220166962A 20/12/2022

Applicant:

SEOUL NAT UNIV R&DB FOUNDATION [KR]
NAT UNIV GYEONGSANG IACF [KR]

US_2022404372_PA

Absstract of: US2022404372A1

The present invention relates to a biomarker composition for diagnosing Johne's disease using the measurement of alpha-2-macrogolublin (A2M) and use thereof.Since the biomarker of the present invention can provide improved sensitivity to subclinical infections by revealing differences in the expressions of host proteins in the serum of MAP-infected subjects during various stages of JD progression, it can be effectively used to eradicate JD from a population of subjects. In particular, since the biomarker of the present invention is detected using the ELISA method, it is possible to diagnose Johne's disease more efficiently than when other methods such as mass spectrometry are used, and it can be directly applied in the field. In addition, it is possible to provide a more excellent diagnostic effect than the existing ELISA kits for diagnosing Johne's disease that are commercially available.

traducir

DIAGNOSTIC MARKER FOR FUNCTIONAL GASTROINTESTINAL DISORDERS

Publication No.: WO2022256861A1 15/12/2022

Applicant:

UNIV NEWCASTLE [AU]
UNIV QUEENSLAND [AU]

Absstract of: WO2022256861A1

Provided herein are methods for diagnosing functional gastrointestinal disorders such as functional dyspepsia and irritable bowel syndrome, comprising detecting IgG antibodies in a sample obtained from a subject, wherein the IgG antibodies recognise one or more antigens from Streptococcus salivarius. Also provided are kits for detecting IgG antibodies for use in the diagnosis of functional gastrointestinal disorders, and methods for selecting subjects for treatment for functional gastrointestinal disorders.

traducir

THERAPEUTIC APPROACH FOR TREATING INFLAMMATORY BOWEL DISEASE

Publication No.: US2022395489A1 15/12/2022

Applicant:

UNIV CALIFORNIA [US]

CA_3155361_PA

Absstract of: US2022395489A1

Provided herein are compositions and methods to that target microbial proteases to ameliorate the intestinal barrier dysfunction and restore mucosal integrity. They are useful to treat and prevent diseases and disorders caused by pathogenic bacteria in the gastrointestinal system of a subject.

traducir

USE OF CANNABIDIOL FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME-RELATED PSYCHOLOGICAL DISTRESS

Publication No.: WO2022251916A1 08/12/2022

Applicant:

EMYRIA [AU]

Absstract of: WO2022251916A1

A method of treating or preventing one or more symptoms of psychological distress in a subject with irritable bowel syndrome, comprising the step of administering a composition comprising from 0.5 mg to 200 mg cannabidiol for at least one month, wherein the subject has at least one symptom of IBS; and symptoms of at least one of anxiety, stress and/or depression when assessed by a validated scale or biomarker for identifying symptoms of anxiety, stress and/or depression and/or the subject has insomnia as assessed by a validated scale or biomarker for identifying symptoms of insomnia.

traducir

USE OF CANNABINOID COMBINATION FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME-RELATED PSYCHOLOGICAL DISTRESS

Publication No.: WO2022251912A1 08/12/2022

Applicant:

EMYRIA [AU]

Absstract of: WO2022251912A1

A method of treating or preventing one or more symptoms of psychological distress in a subject with irritable bowel syndrome comprising the step of:a) administering a composition comprising from 0.5 mg to 200 mg cannabidiol and from 0.5 mg to 200 mg tetrahydrocannabinol for at least one month; wherein the subject has at least one symptom of IBS; and symptoms of at least one of anxiety, stress and/or depression when assessed by a validated scale or biomarker for identifying symptoms of anxiety, stress and/or depression and/or the subject has insomnia as assessed by a validated scale or biomarker for identifying symptoms of insomnia.

traducir

METHODS AND COMPOSITIONS FOR CHARACTERIZING INFLAMMATORY BOWEL DISEASE

Publication No.: US2022390464A1 08/12/2022

Applicant:

CHILDRENS MEDICAL CENTER [US]

WO_2021021735_A1

Absstract of: US2022390464A1

The invention features compositions and methods for characterizing inflammatory bowel disease and inflammatory bowel disease subtypes, such as well Crohn's disease and ulcerative colitis. In one aspect, the invention provides a panel for characterizing inflammatory bowel disease, the panel including two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25) capture molecules each bound to a substrate, wherein each capture molecule specifically binds a marker polypeptide selected from one or more of the following: CD3, CD4, CDS, CD24, CD25, CD27, CD38, CD44, CD45RA, CD45RO, CD127, CD161, CTLA-4, CXCR3, CCR4, CCR6, CCR7, FOXP3, HLA-DR, IFNγ, IL-10, IL-17A, IL-21, IL-22, CD11c, IL23p19, CD66b, CD163, CD44, ckit, CD16, NKp46, AHR, and TNFα, or a polynucleotide encoding said marker polypeptide.

traducir

ANTI-MICROBIAL PEPTIDE (AMP) SIGNATURES FOR DIAGNOSTICS, STRATIFICATION, AND TREATMENT OF MICROBIOME-ASSOCIATED DISEASE

Publication No.: WO2022254430A1 08/12/2022

Applicant:

YEDA RES & DEV [IL]

Absstract of: WO2022254430A1

Proxies for physiological states of tissue are provided. Accordingly, there are provided methods of determining host AMP landscape, establishing a profile indicative of tissue status, and identifying proxies for tissue status in AMP profiles of samples of secretions, exudates and/or excretions of the tissue..Also provided are methods for determination of disease severity and chronology'.

traducir

BIOMARKER OF FIBROSIS

Publication No.: CN115427442A 02/12/2022

Applicant:

北欧生物科技公司

AU_2021257616_A1

Absstract of: WO2021209540A1

The present invention relates to a sandwich immunoassay and kits for detecting in a biological sample cross-linked CTX-III, and its use in evaluating the efficacy of drugs targeting lysyl oxidases (LOXs). Cross-linked CTX-III can be used as a biomarker in diseases associated with fibrosis, including liver fibrosis, chronic intestinal disease, eosinophilic esophagitis and cancer.

traducir

ANTI-MICROBIAL PEPTIDE (AMP) SIGNATURES FOR DIAGNOSTICS, STRATIFICATION, AND TREATMENT OF MICROBIOME-ASSOCIATED DISEASE

Publication No.: IL283563A 01/12/2022

Applicant:

YEDA RES & DEV [IL]
ERAN ELINAV [IL]
ALON SAVIDOR [IL]

WO_2022254430_PA

Absstract of: WO2022254430A1

Proxies for physiological states of tissue are provided. Accordingly, there are provided methods of determining host AMP landscape, establishing a profile indicative of tissue status, and identifying proxies for tissue status in AMP profiles of samples of secretions, exudates and/or excretions of the tissue..Also provided are methods for determination of disease severity and chronology'.

traducir

ANTI-IL-23P19 ANTIBODY REGULATION OF GENES INVOLVED IN ULCERATIVE COLITIS

Publication No.: WO2022251623A1 01/12/2022

Applicant:

LILLY CO ELI [US]

Absstract of: WO2022251623A1

The present disclosure is generally relates to methods of treating and diagnosing ulcerative colitis. The methods are particularly suitable for treating and diagnosing a specific sub-group of patients with ulcerative colitis. The methods are also particularly suitable for treating and diagnosing urgency in a patient having or suspected of having ulcerative colitis. The methods are also particularly suitable for treating and diagnosing stool frequency and bowel urgency in a patient having or suspected of having ulcerative colitis.

traducir

SYSTEMS AND DEVICES FOR DETECTING BIOMARKERS IN SITU AND RELATED METHODS

Publication No.: US2022378363A1 01/12/2022

Applicant:

MASSACHUSETTS INST TECHNOLOGY [US]
UNIV BOSTON [US]
BRIGHAM & WOMENS HOSPITAL INC [US]

WO_2022232188_PA

Absstract of: US2022378363A1

Transient molecules in the gastrointestinal (GI) tract, such as nitric oxide and hydrogen sulfide, are important signals and mediators of inflammatory bowel disease (IBD). Because these molecules may be short-lived in the body, they are difficult to detect. To track these reactive molecules in the GI tract, a miniaturized device has been developed that integrates genetically engineered probiotic biosensors with a custom-designed photodetector and readout chip. Leveraging the molecular specificity of living sensors, bacteria were genetically encoded to respond to IBD-associated molecules by luminescing. Low-power electronic readout circuits (e.g., using nanowatt power) integrated into the device convert the light from just 1 μL of bacterial culture into a wireless signal. Biosensor monitoring was demonstrated in the GI tract of small and large animal models and integration of all components into a sub-1.4 cm3 ingestible form factor capable of supporting wireless communication. The wireless detection of short-lived, disease-associated molecules may support earlier diagnosis of disease than is currently possible, more accurate tracking of disease progression, and more timely communication between patient and their care team supporting remote personalized care.

traducir

ANTI-TREM-1 ANTIBODIES AND USES THEREOF

Publication No.: US2022372139A1 24/11/2022

Applicant:

BRISTOL MYERS SQUIBB CO [US]

JP_2022540674_A

Absstract of: US2022372139A1

Provided herein are methods of identifying subjects suitable for an anti-TREM-1 antibody (i.e., antagonistic anti-TREM-1 antibody) treatment comprising measuring an expression level of a TREM-1 associated gene. Also disclosed herein are methods of determining efficacy of an anti-TREM-1 antibody comprising measuring an expression level of a TREM-1 associated gene. Methods of identifying non-responder to a standard of care treatment and methods of treating a disease or disorder (e.g., inflammatory bowel disease) with an anti-TREM-1 antibody are also disclosed.

traducir

METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE

Nº publicación: US2022372544A1 24/11/2022

Applicant:

MEHARRY MEDICAL COLLEGE [US]

US_2020149087_A1

Absstract of: US2022372544A1

Methods and materials are disclosed for testing biomarkers in a subject suffering from inflammatory bowel disease (IBD) are described herein. Such detection can be useful for diagnosing and treating ulcerative colitis (UC) and Crohn's disease (CD), two forms of IBD that are otherwise difficult to distinguish. The method includes measuring the level of one or more of several biomarkers, including HD5 or MMP-7, which are expressed differentially in patents with UC and CD. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.

traducir

Page1/4 nextPage results/page

punteroimgGo back